Victory Capital Management
FSTX

Victory Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Victory Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,359
Closed -$6K – 3507
2020
Q1 		$6K Buy
+1,359
New +$7.03K ﹤0.01% 3477
2019
Q4 		– Sell
-703
Closed -$10K – 3492
2019
Q3 		$10K Buy
+703
New +$11.6K ﹤0.01% 3278

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ED
Exane Derivatives Paris, France $174M AUM 7.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Victory Capital Management's FSTX Position: Q2 2020 in Review

Victory Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2020, closing a stake of 1,359 shares — an estimated $6K sold.

Victory Capital Management first reported a position in FSTX in Q3 2019 and held it in 2 quarters. The position peaked at $10K in Q3 2019. 25 funds tracked by Wall St. Rank hold FSTX as of Q2 2020.

  • Victory Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,359 F-star Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $10K in Q3 2019.
  • 25 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.